Vical, Astellas Begin Phase III Transplant Trial of CMV Vaccine
Vical Inc. and Astellas Pharma Inc. began a Phase III trial of Transvax, a vaccine for cytomeglovirus (CMV), in 500 hematopoietic cell transplant recipients, with Astellas taking the lead and Vical providing development, regulatory and manufacturing support.
Suite: 1100 | Atlanta, Georgia 30346, USA
Outside of the US
In the U.S. and Canada: +1-877-857-2477
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
Sign up for Highlights FREE e-mail newsletter